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High-throughput targeted 
screening in triple-negative 
breast cancer cells identifies Wnt-
inhibiting activities in Pacific brittle 
stars
Artem Blagodatski1, Vsevolod Cherepanov1,2,3, Alexey Koval3, Vladimir I. Kharlamenko2, 
 Yuri S. Khotimchenko1,2 & Vladimir L. Katanaev1,3
Pro-proliferative oncogenic signaling is one of the hallmarks of cancer. Specific targeting of such 
signaling pathways is one of the main approaches to modern anti-cancer drug discovery, as opposed to 
more traditional search for general cytotoxic agents. Natural products, especially from marine sources, 
represent a largely untapped source of chemical diversity, which so far have mostly been screened for 
cytotoxicity. Here we present a pioneering pipeline of high-throughput screening of marine-based 
activities targeted against the Wnt signaling pathway, which is one of the key factors in oncogenic 
transformation, growth and metastasis in different cancers, including the devastating triple-negative 
breast cancer (TNBC) currently lacking any targeted therapies. This pipeline consisted of collection 
and characterization of numerous invertebrates during the SokhoBio expedition to the Kuril Basin in 
North Pacific, preparation of extracts from these specimen, and their screening in dedicated assays 
monitoring Wnt signaling in TNBC cells. This approach yielded a number of promising hits, including 
highly specific anti-Wnt activities targeting multiple levels within the Wnt pathway from Ophiura 
irrorata and other Pacific brittle stars.
Of all marketed drugs, about 40% originate from natural compounds (either directly or through synthetic modifi-
cations), and this share grows to ca. 50% when looking at small molecule drugs1. Of those, marine-derived drugs 
represent a minority, as their exploitation started only in the 1970s, but are of a high promise, as the chemical nov-
elty and diversity of marine-derived natural products exceeds that of terrestrial sources2,3. Continuing exploration 
of the biodiversity of marine environments will inevitably bring more drugs originating from marine compounds.
Among different disease conditions, cancer has been the target of extensive screenings of natural products as 
the potential source of anti-cancer drugs. These efforts have resulted in appearance of several anticancer chemo-
therapeutic agents, such as camptothecines, anthracyclines, taxanes and vinca alcaloids, either originating directly 
from plants or bacteria or being synthetic derivatives of natural compounds4. The search for marine-derived 
drugs, although started later, has already resulted in some promising anti-cancer agents, such as Eribulin 
(Halaven), Trabectedin (Yondelis) and Brentuximab vedotin (Adcetris), marketed against different forms of can-
cer, such as breast cancer and liposarcoma, soft tissue sarcoma, and lymphomas5.
However, a common feature of most natural product-originating chemotherapeutics is their general cyto-
toxicity: they more strongly affect metabolically active and proliferating cells such as most tumor cells, but are 
also toxic for the healthy cells of the patient. In contrast, development of targeted therapies is the new focus of 
anti-cancer research of the past decades. Such targeted drugs are selective for the cancer cells and have less or 
(ideally) zero toxicity against healthy tissues. Among the hallmarks of cancer, excessively activated signaling 
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pathways that are responsible for continuing proliferation of the cancer cells6 have been one of the major targets 
for the anti-cancer drug discovery, giving rise to several targeted drugs, such as vismodegib – a selective inhibitor 
of the Smoothened receptor suppressing aberrant Hedgehog signaling in the treatment of basal cell carcinoma7.
Several oncogenic signaling pathways exist. In breast cancer (BC) as an example, three major subtypes of the 
disease are identified based on the type of the over-activated signaling pathway driving excessive cell prolifera-
tion8. The first BC subtype is estrogen-receptor positive, receives the command for excessive proliferation from 
over-activation of the estrogen signaling, and is susceptible to targeted anti-hormonal therapies such as tamox-
ifen9. The second subtype relies on over-production of the receptor tyrosine kinase (RTK) HER2 and resulting 
over-activation of the RTK pathway for excessive cell proliferation; the targeted treatment with anti-HER2 mon-
oclonal antibodies, marketed under the trastuzumab (Herceptin) trade names, is typically applied against this BC 
subtype10.
The third BC subtype is negative in expression of estrogen and HER2 receptors, as well as progesterone recep-
tor, as is therefore called triple-negative breast cancer (TNBC). Being insensitive to the existing targeted therapies, 
TNBC accounts for more than half of all BC-related deaths, taking away some 200000 lives annually on the global 
scale11,12. It is widely accepted that one of the most common sources of the pro-proliferation signal in TNBC cells 
is the over-activation of the Wnt signaling pathway13–15. The canonical Wnt signaling pathway plays critical roles 
in embryonic development16 but is also important for the adult life of all metazoans including humans. The path-
way controls cell proliferation and differentiation, and regulates proliferation and self-renewal of various stem 
cells as well as regenerative processes17. Aberrant activation or hyper-activation of the Wnt pathway can lead to 
carcinogenesis in several adult organs, most notably colon18 and breast19. Regarding the TNBC, the Wnt/β-catenin 
signaling, along with other developmental signaling pathways including Cripto-1 and Notch/CSL, is of special 
importance for the regulation of cancer stem cells and for the therapy resistance15. Dysregulation of Wnt signaling 
in TNBC is not only one of the driving forces of initial transformation20 but also promotes cell migration, colony 
formation, stem-like features and chemoresistance, playing important roles also in the later stages of tumor pro-
gression14. Detailed studies on gene expression profiles have subdivided the TNBC into six subtypes, all of which 
demonstrate aberrant overexpression of certain Wnt-associated genes21. Taken together, the modern knowledge 
suggests that in development of targeted treatments against TNBC, Wnt pathway inhibitors should play an essen-
tial though not an exclusive role14. The Wnt pathway is a complex signaling cascade. In humans, it operates with 
19 types of Wnt proteins as ligands and 10 types of Frizzled proteins as receptors. The downstream components of 
the pathway involve a co-receptor LRP 5/6, G-proteins, a multiprotein β-catenin destruction complex (containing 
Axin, APC, glycogen synthase kinase 3β (GSK3β) and casein kinase), β-catenin itself (which serves as a cofactor 
of the key transcription factor TCF inducing expression of the Wnt target genes) and many more cofactors of the 
latter. Taken together, it gives a variety of targets for the inhibition of the pathway22,23.
In TNBC, overexpression of Wnt ligands, the receptor Frizzled7, and the co-receptor LRP6 has been 
described24–26. After that, development of agents targeting the Wnt signaling pathway as future anti-TNBC drugs 
(as well as drugs against other Wnt-dependent cancers) has been initiated. One approach involves development 
of human antibodies against upstream extracellular components of the pathway, such as an antibody against the 
cysteine-rich (extracellular) domain of Frizzled7, which later showed cross-reactivity with 4 other Frizzleds but 
efficiency against several solid cancers in vitro27; phase I clinical studies are currently in place. Screening of librar-
ies of synthetic small molecules is another approach to derive Wnt signaling inhibitors28. Several hit compounds 
have been identified, among them the molecule XAV939 inhibiting tankyrase – a multifunctional enzyme among 
other things regulating the activity of the β-catenin-destruction complex29. Rational drug design and in silico 
screening is also applicable to the Wnt pathway, especially after the recent description of the crystal structure of a 
Wnt-Frizzled complex30; an example of such in silico analysis is our recent identification of an anti-leprosy drug 
clofazimine as a potent inhibitor of the Wnt pathway and growth of TNBC cells in vitro31.
Despite these efforts, no anti-Wnt signaling agents have so far made it to the clinic nor even advanced clin-
ical trials14. As the demand for such drugs to treat TNBC and other Wnt-dependent cancers is urgent, other 
approaches to develop Wnt signaling inhibitors should also be considered. We here describe a paradigm of 
screening for anti-Wnt, anti-TNBC activities from marine sources. Collection of marine invertebrate species 
performed during the SokhoBio expedition32 and extract preparation is hereby followed by high-throughput 
screening for inhibitors of the Wnt pathway in TNBC cells. This approach has resulted in identification of promis-
ing activities from brittle stars of North Pacific and broad characterization of their mode of action within the Wnt 
pathway. Other interesting Wnt inhibitory and activatory activities are also identified in other species. Upscaling 
and further development of this paradigm may promote the discovery of lead compounds to develop treatments 
against the Wnt-dependent cancers.
Results
During the SokhoBio expedition32 of the research vessel “Akademik M.A. Lavrentiev” from 5th of June to 6th 
of August 2015, invertebrate organisms were collected in the Kuril Basin of the Sea of Okhotsk, northwest-
ern Pacific Ocean, at the depths ranging from 1700 to 4750 m (Fig. 1 and Supplementary Table S1). Specimen 
from the following invertebrate groups were collected (Fig. 2 and Supplementary Table S1): Hexactinellidae, 
Polychaetae, Demospongia, Ascidiae, Actiniaria, Sipunculidae, Isopoda, Amphipoda, Echinodermata. Among those, 
the following species were analyzed: Psychropotes longicauda (Holothuroidea: Elasipodida), Molpadia musculus 
(Holothuroidea: Molpadida), Hymenodora glacialis (Malacostraca: Decapoda), Benthodytes incerta (Holothuroidea: 
Elasipodida), Calocarides quinqueseriatus (Malacostraca: Decapoda), Munidopsis antonii (Malacostraca: 
Decapoda), Scotoplanes theeli (Holothuroidea: Elasipodida), Phelliactis callicyclus (Anthozoa: Actiniaria), Atolla sp. 
(Scyphozoa: Coronatae), Umbellula sp. (Anthozoa: Pennatulacea), Gephyrothuria sp. (Holothuroidea: Molpadida), 
Psychropotes sp. (Holothuroidea: Elasipodida), Caprella sp. (Malacostraca: Amphipoda), Eunephthea sp. (Anthozoa: 
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Alcyonacea), Peniagone sp. (Holothuroidea: Elasipodida), Corallimorphus sp. (Anthozoa: Corallimorpharia), and 
Ophiura sp.,including Ophiura irrorata (Ophiuroidea: Ophiurida).
Ethanol extracts (see Methods) from 81 specimens (Fig. 2 and Supplementary Table S1) were screened at 
different dilutions, using the TNBC cell line BT-20 stably transfected with the TopFlash reporter construct, which 
expresses a firefly luciferase under the Wnt-dependent TCF-promoter, so that the luminescence activity of the 
cells reflects the intensity of Wnt signaling31, and stimulated by exogenous Wnt3a (provided as Wnt3a-conditioned 
medium, see Methods). The Wnt3a-conditioned medium is known to be a good substitute for purified Wnt3a 
for cell culturing purposes and possesses a capability to activate the cascade in the luciferase-based and other 
cell culture assays and even to support growth of tissue-based organoids in vitro33. In addition to the TopFlash 
firefly luciferase, which measures Wnt3a-induced transcription, the cells were transiently transfected with the 
CMV-Renilla luciferase reporter a day prior to Wnt stimulation. The Renilla luciferase activity reflects the level of 
general, Wnt-independent transcription (and thus the well-being of the cells). This dual-luciferase assay allowed 
us to normalize the values of Wnt-dependent luminescence by the Wnt independent luminescence in the same 
sample and thus to distinguish between a specific activity of the extracts on the Wnt pathway as opposed to the 
general effect on cellular transcription and/or general cytotoxicity. The assay used in the study is applicable to 
track a Wnt-modulating activity working at any level within the cascade, from the upstream ligand-receptor inter-
action to the downstream transcription factor activity in the nucleus. This allows identifying a broad spectrum of 
potential inhibitors and modulators during the screening, while their exact molecular target can be deciphered 
later using other approaches. The specific activity of the cascade in cells treated only with the Wnt3a-conditioned 
medium (ca. 20-fold over the background), was set to 100%.
This analysis identified 15 extracts from 11 marine invertebrates possessing specific (not affecting general 
transcription), strong (>2-fold reduction) and significant (p-value by the linear regression test <0.05) Wnt 
pathway-inhibitory activity (Supplementary Table S2).
Some of these extracts were produced from single specimen of a single species within a larger animal group, 
such as a decapod crustacean Calocarides quinqueseriatus (reduction of Wnt signaling activity to ca. 10% of con-
trol at 1:400 dilution), a large unidentified polychaete (ca. 50% at 1:300), or a crab Munidopsis antonii (ca. 20% 
at 1:300) (Supplementary Table S2). In some cases, we were able to delineate a specific body part of the inver-
tebrate, which contained the anti-Wnt activity, such as hepatopancreas, but not muscles, of a decapod crusta-
cean Calocarides quinqueseriatus (ca. 10% at 1:400), or skin and muscular sac, but not gonads, of a holothurian 
Molpadia musculus (see further below, Supplementary Table S2).
Much more confidence is provided when different representatives from the same species or of a bigger group, 
collected at different sites, could be compared. Five invertebrate groups stood out in this regard. Holothurians 
Peniagone sp. and Molpadia musculus (skin and muscular sac of the latter), collected at different sites, inhibit the 
Figure 1. Map of the SokhoBio expedition of the research vessel “Akademik M.A. Lavrentiev”, departing 
from and returning to Vladivostok, from 5th of June to 6th of August 2015 in the Kuril Basin of the Sea of 
Okhotsk, northwestern Pacific Ocean. 1 to 11 illustrates the eleven stations where specimens were collected (see 
Supplementary Table S1). Sea depths are indicated. Insert in the upper right corner places the expedition region 
into a bigger map of the North Pacific area. The map was drawn using the QGIS 2.16.1-Nødebo - Quantum 
GIS Geographic Information System, Open Source Geospatial Foundation Project by the “Quantum GIS 
Development Team” (2016) - a free open source geoinformation system software available under following web 
address: http://www.qgis.org/eng/site.
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Wnt pathway in a concentration-dependent manner, down to 30% of control at 1:300 for Peniagone and to 40% 
at 1:100 for Molpadia (Fig. 3a and Supplementary Table S2). Polychaete Travisia sp., various actinias, and gonads 
of Molpadia musculus, in contrast, displayed the ability to co-stimulate the Wnt pathway: activation of the Wnt 
pathway, induced by addition of Wnt3a, became potentiated by 1.5-2 folds if the extract was added together with 
the Wnt3a conditioned medium (Fig. 3b and Supplementary Table S2). Given the importance of the Wnt pathway 
activation in stem cell self-renewal and tissue regeneration17, these unusual co-stimulatory activities from marine 
invertebrates can also be of practical interest22 and will require further elaboration of the exact mechanism of 
action.
The strongest and the most robust effects on the Wnt pathway were seen with the brittle stars (Ophiura). Of 
the five specimens collected at three different stations (station 8 at the depth of 2250 m, station 9 at the depth of 
3340 m, and station 11 at the depth of 3140 m, Supplementary Table S1 and Fig. 1) and belonging to 3 different 
species (Fig. 2) including Ophiura irrorata, all showed a near-complete (down to 2–5% of the control at 1:200 
dilution) and concentration-dependent inhibition of the Wnt pathway, without noticeable effect on the general 
cell transcription (Supplementary Table S2 and Fig. 4a,b).
Focusing on Ophiura irrorata, we next roughly assessed where in the Wnt signaling pathway the molecular 
target of the active component(s) of this brittle star could be located. To address this, we compared the ability of 
the extract to inhibit the Wnt pathway when activated by Wnt3a vs. LiCl at 15 mM (a concentration within the 
standard range for induction of the Wnt signaling in cultured cancer cells31,34,35). LiCl inhibits GSK3β, a compo-
nent of the β-catenin destruction complex, and thus activates the pathway at the cytoplasmic level bypassing the 
reactions occurring at the plasma membrane and its vicinity36. We found that O. irrorata could also inhibit this 
LiCl-induced Wnt pathway activation (Fig. 4c). Curiously, only the highest tested concentration of the extract 
(the 1:100 dilution) could elicit a clear inhibition of the LiCl-induced pathway activation; further, the induced 
reduction was only ca. two-fold (Fig. 4c). This contrasts with the near-complete inhibition of the Wnt3a-induced 
response, already seen with lower concentrations of the extract, and IC50 achieved at the ca. 1:400 extract dilution 
(Fig. 4a,b).
Discussion
Brittle stars (Ophiuroidae) is the largest class of echinoderms, with >2000 species known, of which ca. 400 species 
reside in the North Pacific37. Our finding that specimens from three different Ophiura species collected at differ-
ent locations possess promising activities, inhibiting the Wnt pathway in TNBC cells, hints at the possibility that 
the same (classes of) anti-Wnt compound(s) may exist in other brittle stars.
Figure 2. Photographs (not in scale) of representatives of the ca. 80 invertebrate specimens analyzed in this 
study. Specimen number(s) is provided below each image. Color coding refers to each of the eleven stations, 
where the specimens were collected (see Supplementary Table S1 and Fig. 1).
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Pacific brittle stars have been the source of terpenes and phenylpropanoids (Ophioplocus japonicus38, ster-
oid sulfates (Ophiopholis aculeata, Ophiura sarsi, and Stegophiura brachiactis39, gangliosides (Ophiura sarsi and 
Ophiocoma echinata40, Ophiomastrix annulosa41, and Ophiocoma scolopendrina42, and other compounds, some of 
which are further shared among other echinoderms. Multidimensional fractionation of extracts from O. irrorata 
or other brittle stars, coupled with activity characterization, followed by structure elucidation, are awaiting to 
identify the molecular nature of the anti-Wnt components we have described here. Subsequent tests in vitro and 
in vivo against TNBC (and other Wnt-dependent cancers) will be performed in order to advance these molecules 
along the path of the anti-cancer drug development35. With the recent draft genome sequencing of the brittle star 
Ophionereis fasciata43, potential molecular biology and genetic engineering approaches to characterization and 
biotechnological applications of the brittle star metabolome will be facilitated.
Extracts from the Persian Gulf Ophiocoma erinaceus have been reported to possess anti-proliferative activ-
ity against A2780cp cells, and anti-angiogenic activity in the fertilized Ross egg model44. Using HeLa cells, 
anti-migration and pro-apoptotic activities were reported45, and the latter were found to be mediated by the 
polysaccharide fraction of the O. erinaceus extracts46, while the anti-migration activity – by the saponins47. Pacific 
O.japonicus terpenes were also reported to have a certain cytotoxic activity38.
However, we must stress here the fundamental difference of our marine natural product-based drug discovery 
approach from those traditionally applied in the past and also now by many laboratories. We are explicitly not 
looking for cytotoxic agents. Furthermore, such activities are eliminated during our screening process. Instead, 
we look for natural compounds targeting one of the hallmarks of cancer – pro-proliferative oncogenic signal-
ing6, with a special focus on Wnt signaling responsible for oncogenic transformation, growth and metastasis in 
a number of tissues, including the breast22. Of note, inhibition of Wnt signaling in breast cancer cells causes cell 
proliferation arrest but not cell death26,31,35.
The fact that the Ophiura irrorata extract inhibits LiCl and Wnt3a-induced response with different efficien-
cies suggests that several Wnt-modulatory components exist in brittle stars, acting at different molecular targets 
within the pathway. One of these targets lies above, and one – below GSK3β. We are particularly interested in the 
component(s) active against the higher-located molecular target(s). Indeed, inhibitors of the Wnt pathway acting 
below GSK3β are known to bluntly suppress all the tissue-specific subtypes of the pathway. Thus, not only the 
oncogenic Wnt signaling, but also physiologic involvements of the pathway relevant e.g. for renewal of epithelial 
cells in the gastrointestinal tract will be affected producing strong side effects. Instead, it is more promising to 
Figure 3. Extracts showing specific Wnt pathway-modulating activities in TNBC cells, across multiple 
representatives of same invertebrate groups collected at different sites. (a) Extracts from holothurians can 
robustly and specifically inhibit the Wnt pathway. Extracts from Peniagone sp. (specimens 59 and 94) are shown 
in red, and from the skin and muscular sac of Molpadia musculus (specimens 4, 37, 54, 86) in blue. The X-axis 
reflects the dilution of the extract (i.e. the final part of the extract in the culture media, such that dilution of 0.01 
corresponds to the 1:100 dilution). The Y-axis shows the activity of the Wnt-dependent luminescence, 
normalized to the Wnt-independent Renilla luminescence, setting to 100% the normalized luminescence activity 
of cells treated with the Wnt3a-conditioned medium without any extract added. Curves are fit using the equation: 
= −
+
y ax bx
c x( )
, providing c as the IC50 of the extract-induced inhibition, which is 0.0019 (1:526 dilution) for 
Peniagone sp. and 0.0121 (1:83 dilution) for the skin and muscular sac of Molpadia musculus. (b) Co-activation of 
the Wnt pathway can be observed for extracts (all shown for the 1:100 dilution) from several invertebrate groups: 
polychaete Travisia sp. (specimens 7, 17, 53, 64, 65), various Actinias (specimens 16, 44, 55, 78), and gonads of 
M.musculus (specimens 9, 60, 90). Data are presented as mean ± sem. “*” signs highlight experimental points 
with statistically significant pairwise difference from control (no extract added) as determined by the two-way 
ANOVA (a) and the Student t-test (b); p value < 0.05 is indicated as “*”,  <0.01 as “**”,  <0.001 as “***”,  and 
<0.0001 as “****”. Photographs of the specimens are provided on each panel. “n” stands for the number of 
experiments.
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selectively target the upper levels of the pathway, where more variability among the signaling subtypes is provided 
in different tissues and in different contexts (i.e. physiologic vs. pathologic)22,28,48.
We consider the pipeline of marine-based drug discovery presented here to represent a pioneering approach to 
deliver novel targeted drug candidates. This pipeline is composed of invertebrate collection during dedicated sea 
expeditions, specimen extraction, screening using specific assays monitoring oncogenic signaling in cancer cells, 
and preliminary characterization of the mode of action of the hit extracts within the pathway. As exemplified in 
this report, such an approach has resulted in identification of promising anti-Wnt and Wnt pathway-modulating 
activities in Ophiura species and also in a number of other invertebrates. Subsequent work will advance these 
activities towards drug candidates, but also will feed more marine organisms into this pipeline.
Methods
Specimen collection and extraction. Invertebrates were collected using the Agassiz Trawl and the 
epibenthic sledge from depths of 1700–4750 m in the Kuril Basin, Sea of Okhotsk, and adjacent deep-sea area 
of the Pacific Ocean during the SokhoBio expedition of the research vessel “Akademik M.A. Lavrentiev”32 
(Supplementary Table S1 and Fig. 1). The specimens were placed in 10 ml 80% ethanol immediately after col-
lection and extracted by storage at 4 °C for 6 months. Each extract sample was derived from a single individual 
organism of the size average for its species. In case of separate organs or body parts, they were dissected imme-
diately after catch and placed separately into 10 ml 80% ethanol. Before experiments, the ethanol solution, in 
which the samples had been stored, was collected and centrifuged to remove the debris; the supernatants were 
concentrated 100-fold in the following way: 1 ml of the extract was put in a 1.5 ml tube and evaporated under 
vacuum at 30 °C using the Eppendorf concentrator 5301. The dry pellet was then re-dissolved in 10 μl DMSO and 
stored at −20 °C.
Ethics statement. Invertebrate sample collection was performed by the standards approved by the Ministry 
of Education and Science (Russia), and Federal Ministry of Education and Research (Germany). All efforts were 
made to minimize suffering.
Wnt3a-conditioned medium. The Wnt3a-conditioned medium was obtained by culturing mouse L-cells 
stably transfected with Wnt3a (A.T.C.C. catalogue number CRL-2647) with the initial confluency of 10–20% 
for 4 days in DMEM (Dulbecco’s modified Eagle’s medium) supplemented with 10% FBS (fetal bovine serum; 
HyClone), as described49. Before utilization, the medium was centrifugated at 4000 g for 5 min, filter-sterilized 
(0.22 µm), tested for its ability to activate Wnt-dependent luminescence over the background level in BT-20-Tf 
cells (see below), aliquoted and stored at −20 °C.
Luciferase-based assay of the Wnt-dependent transcriptional activity. BT-20 (A.T.C.C. catalogue 
number HTB-19), a triple-negative human mammary carcinoma line cells stably transfected with the M50 Super 
8 × TopFlash plasmid31 were used to analyze the Wnt modulatory activities of extracts from marine inverte-
brates. The assay was performed in white tissue-culture-treated 96-well plates (Greiner). The BT-20-Tf cells were 
seeded in 100 μl of DMEM containing 10% FBS at ca. 10000 cells/well, incubated overnight at 37 °C, 5% CO2 and 
subsequently stimulated by 50 μl of the Wnt3a-conditioned medium or LiCl (to 15 mM) in the presence of the 
invertebrate extracts to the final concentration of DMSO of 0.25%, or DMSO alone, for 12–24 h. If indicated, the 
cells were additionally transiently transfected by the pCMV-RL plasmid (purified with Quiagen Plasmid Midi 
Kit 12145) for constitutive expression of Renilla luciferase50 using XtremeGENE 9 reagent (Roche) according to 
Figure 4. Different ophiuras possess strong and specific anti-Wnt activity in TNBC cells. (a,b) Extracts from brittle 
stars collected at station 11 (Ophiura irrorata, specimens 22 and 47), 8 (Ophiura sp. #1, specimens 38 and 98),  
and station 9 (Ophiura sp. #2, specimen 76), all strongly inhibit the specific Wnt-dependent transcription in 
a concentration-dependent manner. Curves in (a) display representative experiments performed with the 
indicated specimens. Curve fitting in (b) is done as in Fig. 3, with the resulting IC50 of 0.0026 (extract dilution 
of 1:385). (c) Extract from Ophiura irrorata (#22) also inhibits, in a concentration-dependent manner, Wnt 
pathway activation induced by 15 mM LiCl. Due to incomplete inhibition, IC50 of the inhibition of the LiCl-
induced response cannot be adequately calculated. Statistical analysis in (b,c) is performed with the 1-way 
ANOVA. Data presentation is as in Fig. 3. For each dataset in (c), n = 3.
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the manufacturer’s protocol 16–24 h prior to treatment with the Wnt3a conditioned medium and the extracts. 
The medium was subsequently removed and 15 μl of the lysis buffer (25 mM glycylglycine, pH 7.8, 1% Triton 
X-100, 15 mM MgSO4, 4 mM EGTA, 1 mM DTT) were pipetted into each well. After incubation for 5 min at room 
temperature, the 96-well plate was analyzed using the Victor3 Multilabel Counter (PerkinElmer) or Cytation 5 
(Biotek) with the two-channel dispensing unit primed with the buffer solutions for separate activity measure-
ments of firefly and Renilla luciferase, prepared as described51. The final volumes dispensed per well were 50 μl of 
firefly and 50 μl of Renilla solutions.
Electronic supplementary material. The online version of this article contains supplementary material 
(Supplementary Tables S1 and S2), which is available to authorized users.
Data availability statement. All data generated or analysed during this study are included in this pub-
lished article and its Supplementary Information files.
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